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The Hepatitis E virus (HEV) is an emergent virus that causes acute hepatitis in 
immunocompetent hosts and chronic hepatitis in immunocompromised hosts. In Latin 
America, the main circulating genotype HEV-3 is usually of zoonotic origin. Diagnosis and 
seroprevalence studies mainly rely on the detection of specific antibodies. There are scarce 
data on the seroprevalence of HEV infection in Latin America mainly due to the lack of 
awareness of HEV circulation. Furthermore, in some countries, like Argentina, HEV testing 
is not included in routine assays. In order to provide tools to deepen the knowledge on 
HEV epidemiology in South America, we designed a new in-house ELISA based on the 
native recombinant protein ORF2 aa112–608 and demonstrated its potential for detecting 
anti-HEV immunoglobulin G (IgG) in human serum samples. The following conditions were 
determined: an optimal antigen concentration of 0.25 μg/ml, a serum dilution of 1:80, 
gelatin as a blocking agent, and a secondary antibody dilution of 1:2000. A relative sensitivity 
of 93.33% (95% CI: 77.9–99.2%) and a relative specificity of 99.4% (95% CI: 96.7–100%) 
were determined using a panel of previously characterized sera and a gold standard (HEV 
IgG ELISA, DIA.PRO, Italy). Further, we obtained a very good agreement (κ index = 0.94, 
95% CI: 0.87–1.00) with the gold standard. We screened 813 blood donor samples with 
this newly developed ELISA and found a seroprevalence of 9.23% (95% confidence interval, 
7.33–11.43%). We show for the first time evidence of past HEV infection in Tucuman, the 
most populated city in northern Argentina. We expect that this study will raise the interest 
of health decision makers who should intercede to include indirect testing of HEV in regular 
diagnostic protocols. In conclusion, the in-house ELISA developed in this work shows a 
very good agreement with an already licensed commercial HEV IgG ELISA (DIA.PRO, 
ITALY), which can be used as an epidemiologic tool for HEV surveillance.
Keywords: hepatitis E virus, enzyme-linked immunosorbent assay, seroprevalence, blood donors, 
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INTRODUCTION
The Hepatitis E virus (HEV) is an emergent virus that is 
causing hepatitis worldwide. The clinical presentation of HEV 
infection varies from mild and self-limiting to severe cases 
with typical features of hepatitis: malaise, abdominal, muscle 
and joint pain, anorexia, and jaundice (Purcell and Emerson, 
2008; Lewis et  al., 2010), which can end up as fulminant 
hepatitis. Furthermore, chronic hepatitis has recently been 
reported in patients with immune disorders and that is hepatically 
compromised (Bricks et al., 2019; Yang et al., 2019). For unclear 
reasons, the incidence of fulminant hepatitis in pregnant women 
is up to 20% (Purcell and Emerson, 2008; Lewis et  al., 2010). 
Several extra-hepatic manifestations such as arthralgia, Guillain-
Barré syndrome, meningitis, and others have been attributed 
to HEV infection (Krain et al., 2014; Dalton et al., 2016; Pasha 
et  al., 2018). These aspects of the disease underline the need 
to further investigate HEV, improve diagnostics, and increase 
the awareness of its circulation.
HEV-3 circulates in several countries in Europe and America 
and is transmitted zoonotically mainly by wild boars, domestic 
pigs, and deers. HEV genomic RNA and replication 
intermediates have also been detected in donkeys, goats, horses, 
macaques, mongoose, rabbits, rats, and sheep (Pavio et  al., 
2010; Kenney, 2019). The main infection mechanism seems 
to be  the consumption of contaminated raw or undercooked 
meat (Cai et  al., 2017; Cook et  al., 2017) or contact with 
infected animals (Vonesch et  al., 2019). Certain concern has 
arisen regarding the need to control blood transfusion units 
for the presence of HEV nucleic acids (Kraef et  al., 2018; 
Harvala et  al., 2019; Rivero-Juarez et  al., 2019). Still, there 
is no clear consensus on whether HEV detection should 
be  included in routine blood product screenings.
Hepatitis E can be diagnosed by the detection of viral RNA 
in blood and feces by end-point RT-PCR or qRT-PCR, but 
more accessible diagnostic assays are ELISA or immunoblotting 
to detect specific antibodies. Direct-to-consumer-testing 
laboratories in developing countries have limited access to HEV 
diagnostic tests. In South America, there is scarce data on 
the epidemiology of HEV. HEV-1 has been detected only in 
Venezuela and Uruguay in isolated cases (Mirazo et  al., 2014). 
In the rest of the continent, HEV-3 has been isolated from 
patients and environmental samples; the most frequent subtypes 
reported were: −3a, −3b, −3c and −3i, which were related 
to European, American, and Japanese strains (Pisano et  al., 
2018b). In the 1990s, a 1.8% seroprevalence of anti-HEV 
antibodies was found in blood donors (n  =  2,157 samples) 
in Buenos Aires (Rey et  al., 1997). The next epidemiological 
study looking for specific anti-HEV antibodies in blood donors 
was carried out also in Buenos Aires in 2012 by Munne et  al. 
who found a seroprevalence of 10.6% in 123 adults voluntarily 
screened on the World Hepatitis Day (Munne et  al., 2014).
Further evidence of past infections was found in 
epidemiological studies of specific patient groups such as 
immunocompromised individuals (HIV positive and transplant 
recipients) and patients undergoing dialysis in other regions 
of Argentina. No differences with a control group (4.3%) were 
found in transplant recipients (5.8%; Pisano et al., 2017), while 
a higher seroprevalence of antibodies to HEV (7.3%) was found 
in HIV-positive patients (Debes et  al., 2016) and patients 
undergoing hemodialysis (10.2%; Pisano et al., 2017) in Argentina, 
similar to findings in other countries. In a serological survey 
conducted in 433 patients attending primary care centers in 
the central region of Argentina, the seroprevalence for antibodies 
to HEV as detected with a commercial kit (HEV IgG ELISA, 
DIA.PRO, Italy) was 4.4% in 2011 (Martinez Wassaf et  al., 
2014). In the central region of Argentina, the seroprevalence 
of HEV in blood donors was much lower with a value of 
1.81% in 1997 and later, in 2012 the seroprevalence increased 
to 9% (Rey et  al., 1997; Munne et  al., 2014). Recently, a 
surprisingly high HEV seroprevalence of 40.25% was reported 
in Brazil using an in-house ELISA, suggesting that in this 
region of Brazil, HEV is endemic (Pandolfi et  al., 2017).
In Argentina, only one HEV ELISA kit is available imported 
from Italy and distributed from Buenos Aires to the entire 
country. This kind of monopoly is associated with higher costs, 
longer delays, and diminished accessibility. A way to circumvent 
this caveat is the development of in-house assays.
Therefore, we aimed to develop an ELISA to detect anti-HEV 
IgG antibodies that can be  used for surveillance purposes and 
as a tool to gain knowledge on HEV epidemiology.
MATERIALS AND METHODS
Recombinant Cloning of Hepatitis E 
Virus-3 ORF2
The viral antigen used in the development of the in-house 
ELISA was 66 kDa recombinant polypeptide comprising aa112–608 
of the capsid protein of HEV-3. A pMK plasmid containing 
the coding sequence for ORF2 flanked by attB sites was obtained 
by synthesis at GeneArt Gene (TermoFisher Scientific) based 
on the ORF2 available sequence in GenBank BAG15899.1 
(Takahashi et  al., 2008) and further subcloned into pETG-A-
His-N-[rfB] using an LR clonase (Gateway® recombinatorial 
cloning) as described by Vizoso Pinto et  al. (2010). Briefly, 
the LR reaction was set using 1  μl entry vector 
pMK-HEV3ORF2aa112–608, 1  μl destination vector pETG-A-His-
N-[rfB], 1 μl LR clonase, and 2 μl extra pure water; the reaction 
was incubated 2  h at 37°C and transformed in E. coli DH10B 
by heat shock. After this, bacterial cells were plated onto LB 
agar added with ampicillin (100  μg/ml) and grown o.n. At 
least two colonies were selected, grown o.n. in LB added with 
ampicillin after which the plasmid was purified using a High 
Pure Plasmid Isolation Kit (Roche). Plasmids were checked 
by enzyme restriction with HindIII and XbaI (New England 
Biolabs) followed by agarose electrophoresis.
Expression and Purification of RGS-His5-
Tagged Hepatitis E Virus-3 ORF2
Chemically competent E. coli Rosetta (DE3) was transformed 
with pETG-A-His-N-ORF2 by heat shock and selected on LB 
plates supplemented with 100  μg/ml ampicillin and 17  μg/ml 
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chloramphenicol. Several transformants were selected and kept 
in LB medium supplemented with 25% glycerol at −20°C. 
Overnight cultures were inoculated in fresh medium and grown 
for 2  h, after which protein expression was induced with 
different concentrations of IPTG (0.25, 0.5, 1.0, or 2.0  mM) 
during 1–5  h, or overnight, and at 30°C or 37°C. After 
centrifugation, bacterial pellets were resuspended with ice-cold 
lysis buffer (10% glycerol, 20 mM Tris-HCl, 0.5 M NaCl, 5 mM 
imidazole, pH 7.9, supplemented with 0.02  mg/ml DNAse, 
0.1% Triton, 0.2 mM PMSF, 1 mM DTT, and 1 mg/ml lysozyme) 
and incubated on ice for 1  h. Cells were lysed by 3  cycles of 
freeze-thawing. The supernatant was separated by centrifugation 
and kept as the soluble fraction. Then, inclusion bodies were 
solubilized in a buffer containing 0.5 M NaCl, 5 mM imidazole, 
20  mM Tris–HCl, and 8  M urea pH 7.9. The ORF2 protein 
was purified under native and denaturing conditions using 
NiNTA chromatography (Thermo Fisher Scientific) following 
the manufacturer’s instructions. Expression and purity of 
recombinant proteins were analyzed by SDS/PAGE followed 
by staining and verified by Western blotting using a mouse 
monoclonal anti-RGS-His antibody (Qiagen, Germany). Purified 
proteins were stored at −70°C. Protein concentration was 
determined with Bradford’s reagent (BioRad) following the 
manufacturer’s instructions.
Serum Samples
To determine the cut-off value and performance of the in-house 
ELISA (specificity, sensitivity, ROC curve, and κ index), we used 
a panel of 197 serum samples (30 HEV IgG positive and 167 
HEV IgG negative sera) obtained as follows: 24 serum samples 
belonged to patients with signs and symptoms of hepatitis 
and elevated transaminases of unknown origin, which were 
previously searched for total antibodies to HEV using the HEV 
Ab ELISA (DIA.PRO, Italy) for diagnostic purposes at CEMIC. 
Only two of the sera were also RT-PCR positive (LightMix®, 
Modular Hepatitis E Virus, Roche SAP), and the amplified 
product was sequenced and corresponded to genotype 3. Further, 
only five of these samples presented specific IgM antibodies 
to HEV as determined with the HEV IgM ELISA (DIA.PRO, 
Italy). Two of the samples were anti-HEV IgG positive samples 
from Inst. Malbran. A further, three anti-HEV IgG positive 
and 121 negative anti-HEV IgG samples belonging to our blood 
donor panel were also screened with HEV IgG (DIA.PRO) 
and therefore included in the characterized panel. All 197 
samples were retested in duplicate using the HEV IgG (DIA.
PRO) to confirm the results provided before.
Enzyme-Linked Immunosorbent  
Assay In-House
To develop an assay to detect specific anti-HEV IgG antibodies, 
we  optimized the antigen (recombinant ORF2) concentration, 
the dilution of serum, and the dilution of secondary antibody; 
we  chose among three different blocking agents and tested 
the optimal TMB concentration. High-protein binding 96-well 
plates (JetBiofil® and Nunc®) were coated with the purified 
antigen and diluted in carbonate buffer at different concentrations 
(0.1–20  μg/well). Plates were incubated overnight at 4°C. The 
wells were washed with PBS, added with 0.5% Tween-20 (PBST), 
and then blocked with 1% (v/v) gelatin (Sigma), 5% skim 
milk or 1% BSA and diluted in PBST. Human sera were serially 
diluted to find the optimal dilution, added to the plates, and 
incubated at 37°C for 60 min. Then, a HRP-secondary antibody 
(Dako) was tested at different dilutions, added to the wells, 
and incubated at 37°C for 60  min. The plates were washed 
with PBST and revealed with 0.1  mg/ml substrate 
(3,3′,5,5′-tetramethylbenzidine, Sigma), and the reaction was 
stopped with 1  M phosphoric acid. Plates were read on an 
ELISA reader (Allshen) at 450  nm.
Evaluation of the In-House Enzyme-Linked 
Immunosorbent Assay Performance
To find the most appropriate cut-off value and to describe 
the test thoroughly, receiver-operated characteristic (ROC) 
analyses and calculated area under the curves (AUCs) were 
performed to achieve minimum target values for both sensitivity 
and specificity along with corresponding estimates and a Wilson 
binomial confidence interval. Agreement between the commercial 
and the in-house assays was assessed by pairwise comparisons 
using the κ coefficient.
To determine the detection limit of the assay, we  serially 
diluted a WHO HEV serum standard (NIBSC 95/584) and 
tested the dilutions on the in-house ELISA plate.
The intra-assay variability was calculated as an average from 
the individual coefficients of variation (CV) from well to well 
of high, low, and negative anti-HEV-IgG samples within the 
same plate (10 replicates each). The inter-assay precision was 
calculated from the individual coefficients of variation (CV) 
from well to well of high, low, and negative anti-HEV-IgG 
samples from different plates. Acceptable criteria for intra- and 
inter-assay variability were defined as coefficient of variation 
(CV) <10 and <15%, respectively. Acceptable criteria for 
functional sensitivity were CV <20% (Pisanic et  al., 2017).
Commercial Enzyme-Linked 
Immunosorbent Assay
We determined the presence of anti-HEV IgG antibodies in the 
197 serum samples of the panel using the only commercially 
available kit in Argentina (HEV IgG ELISA, DIA.PRO, Italy) 
according to the manufacturer’s instructions. The HEV IgG ELISA 
(DIA.PRO) is a qualitative test. Its microplates are coated with 
HEV-specific synthetic antigens encoding for conservative and 
immunodominant determinants derived from Mexican and Burmese 
virus strains. Serum is diluted 1:100 before testing. We  used the 
cut-off value 0.3515 and calculated as A450  nm (negative control)  +  0.350, 
as suggested by the test’s leaflet.
Seroprevalence Study
The minimal sample size necessary to determine the 
seroprevalence in blood donors of Tucumán was 126 serum 
samples, as calculated using the InfoStat software and the 
EpiTool considering an estimated seroprevalence of 7% (a mean 
value of the seroprevalence reported for other regions in 
Arce et al. Novel In-House ELISA for HEV
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Argentina) with a confidence level of 95%, a desired precision 
of 5%, and the sensitivity and specificity values obtained for 
the in-house ELISA (93.3 and 99.4%, respectively). Nevertheless, 
a larger number with a total of 813 blood bank serum samples 
collected in 2017 were included in the present study. Briefly, 
the median age was 35. Most of the participants (73.05%) 
were male, and 34.22% were between 26 and 35  years old. 
The protocol was approved by the Committee on Research 
Ethics of the SI.PRO.SA. (Sistema Provincial de Salud, Tucumán, 
Argentina, case file 849,709). The in-house HEV ELISA was 
used to determine anti-HEV IgG seroprevalence in 813 blood 
donors of Tucuman, Argentina.
Statistical Analysis
The receiver operating characteristic (ROC) curve was used 
to assess the optimal cut-off values for interpretation of the 
results obtained with the in-house ELISA. Sensitivity and 
specificity were calculated.
The agreement between the in-house ELISA and the 
commercial ELISA (HEV IgG, DIA.PRO, Italy) was assessed 
using Cohen’s κ coefficient. Confidence intervals were calculated 
according to the binomial (Clopper-Pearson) “exact method” 
bases on the β distribution. We used χ2 at a 95% CI to compare 
differences between categorical variables. The values of p <0.05 
were considered statistically significant. Confidence intervals 
were calculated according to the binomial (Clopper-Pearson) 
“exact method” bases on the β distribution. All analyses were 
conducted using EpiTools1.
CV% in the intra- and inter-assay variability was calculated 
with Excel® (Windows®).
RESULTS
Recombinatorial Cloning of Hepatitis E 
Virus-3 ORF2
After subcloning, the recombinant plasmids were confirmed 
by double restriction enzyme digestion (HindIII and XbaI) 
followed by electrophoresis on 1% agarose (data not shown).
Expression and Purification of RGS-His5-
Tagged Hepatitis E Virus-3 ORF2
We selected and worked with the best clone among several 
different E. coli Rosetta ORF2-expressing ones. Protein expression 
was induced optimally with 1  mM IPTG when A595nm reached 
a value of 0.6 after shaking at 37°C for 3  h. The RGS-His5-
tagged ORF2 protein was purified by NiNTA chromatography 
(Thermo Fischer Scientific) at higher yields under native 
conditions than under denaturing conditions, suggesting that 
most of the protein was present in the bacterial cytoplasm. 
The expression of the truncated ORF2 protein was checked 
by SDS-PAGE and Western blotting using an anti-RGS-His5 
1 Sergeant, ESG, 2019. Epitools epidemiological calculators. Ausvet Pty Ltd. 
Available at: http://epitools.ausvet.com.au
antibody and a HEV positive serum (data not shown). Under 
native conditions, ORF2 protein forms dimers and trimers; its 
yield was approximately 4.93  mg/L.
Optimal Conditions for Developing  
an In-House Enzyme-Linked 
Immunosorbent Assay
The ELISA was optimized by comparing native and denatured 
antigens, different antigen concentrations, serum dilutions, and 
blocking agents, and two different plate brands. We  first tried 
native and denatured antigens and selected the former for 
further development because of its better performance and 
yield. Then, we found the best dilution of the secondary antibody 
to be  10  μg/ml coating antigen with 5% milk as blocking 
agent (Figure 1A). Afterward, we  selected the optimal serum 
dilution according to reactivities observed by coating plates 
with three different antigen concentrations (1, 10, and 20  μg/
ml) plus 5% milk as blocking agent (Figure 1B). The optimal 
serum dilution tested was 1:80 (Figure 1C). For optimizing 
the relation between the positive and the negative samples 
(P/N), we  diluted the coating antigen and tested in three 
blocking agents (Figure 1D); when plates were blocked with 
milk, negative samples exhibited a much higher background 
than with gelatin or BSA (p  <  0.05). Thus, we  selected a 
coating antigen concentration of 0.25  μg/ml, a serum dilution 
of 1:80, a secondary antibody dilution of 1:2000, and 1% gelatin 
as blocking agent. Finally, we  tested two different brands of 
high-protein binding 96-well plates (Nunc Polysorb and JetBiofil), 
but they did not differ significantly from each other (data not 
shown). JetBiofil plates were chosen because they gave a better 
cost-benefit ratio.
Relative Specificity Sensitivity  
of the In-House Enzyme-Linked 
Immunosorbent Assay
To calculate a proper cut-off value, receiver-operated characteristic 
(ROC) and two graph ROC curve analyses were performed using 
a panel of 197 characterized serum samples resulting in a cut-off 
value of A450 = 0.498 (Figures 2A,B). The high area under curve 
(AUC) value of 0.988 (95% CI: 0.976–1.0) reflects the high 
accuracy of the assay (Figure 2A). Further, we  compared our 
in-house ELISA with a commercial assay (HEV IgG ELISA, DIA.
PRO; Table 1). We  calculated a relative sensitivity of 93.33% 
(95% confidence interval, 77.93–99.18%) and a specificity of 99.4% 
(95% confidence interval, 96.71–99.98%; Table 1) at the selected 
cut-off value of A450nm  =  0.498. The κ agreement test yielded a 
high score of 0.9402 (0.8731–1.0073), reflecting a strong to very 
good agreement with the DIA.PRO HEV ELISA test (Table 1).
Detection Limit and Variability Intra- and 
Inter-Assay
We tested serially diluted samples of the HEV WHO standard 
on to the in-house ELISA plate. As a result, the lowest 
concentration detected by the assay was 0.25  IU/ml, while the 
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detection limit of the DIA.PRO ELISA is 0.2  IU/ml according 
to reports in a comparative study done with five different assays 
(Norder et  al., 2016). We  found that the intra-assay variability 
of negative, low, and high positive HEV-IgG samples (10 replicates 
each) was 8, 4, and 4%, respectively, whereas the inter/assay 
variability was 6, 8, and 4%, respectively (data not shown).
Seroprevalence of Anti-Hepatitis E Virus 
Immunoglobulin G in Blood Donors
We screened 813 serum samples from blood donors collected 
in Tucumán in 2017. We found 75 positive samples for anti-HEV 
A B
C D
FIGURE 1 | Optimal conditions for the in-house ELISA. Serum samples previously determined as positive or negative for anti-HEV IgG with the commercial kit (DIA.
PRO) were used. The optimal dilutions of serum samples (A) and of the secondary antibody were determined (B) using an antigen concentration of 10 μg/ml. Serum 
samples positive for anti-HEV IgG or negative for anti-HEV IgG, as previously determined with the commercial assay, were used. (C) Optimal antigen concentration 
at three serum dilutions 1:20 (black balks), 1:40 (light gray balks) and 1:80 (dark gray balks) and (D) different blocking agents. P/N ratio in (B–D) is calculated as the 
relation A(λ 450 nm) positive sample/A(λ 450 nm) negative control.
A B C
FIGURE 2 | ROC curve, sensitivity and specificity graph of the in-house ELISA, and seroprevalence of anti-HEV IgG antibodies in blood donors. (A) ROC curve 
obtained with 197 characterized sera for their reactivity to HEV. (B) The cut-off value of the assay (A450nm values = 0.498) as determined by the optimal values of the 
sensitivity (dashed gray line) and specificity (full black line) curves. (C) Prevalence of anti-HEV antibodies in 813 blood donors. Results are depicted as absorbance 
values at λ = 450 nm. Samples with A450nm values > 0.498 were considered as positive using the optimal parameters determined before for the ELISA.
TABLE 1 | Performance of the in-house ELISA compared to the commercial 
ELISA (DIA.PRO) in detecting anti-HEV IgG.
Commercial ELISA
Positive Negative Total
In-house ELISA Positive 28 1 29
Negative 2 166 168
Total 30 167 197
Relative sensitivity 93.33% (95%CI, 77.93–99.18%)
Relative specificity 99.4% (95%, 96.71–99.98%)
κ 0.9402 (95%CI, 0.8731–1.007)
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IgG using the in-house ELISA (Figure 2C). Thus, the overall 
seroprevalence for anti-HEV IgG was of 9.23% (Clopper-Pearson 
exact 95% confidence interval, 7.33–11.43%). HEV seropositivity 
was independent of sex (p  =  0.3015) and age (p  =  0.8376).
DISCUSSION
We developed a HEV-3 ELISA based on the ORF2 recombinant 
protein produced in E. coli under native conditions. The protein 
ORF2 is the structural component of the capsid, the most 
immunogenic HEV protein, and the antigen of choice for 
serological diagnostics (Table 2). The C-terminal region is 
exposed on the surface of the capsid and harbors neutralizing 
epitopes, whereas the N-terminal region is hidden within the 
particle (Mori and Matsuura, 2011; Tang et  al., 2011; Shata 
et  al., 2012). Most of the assays reviewed in Table 2 are 
based on denatured ORF2 protein, which exposes the linear 
epitopes but not the conformational ones. Our assay differs 
from others (Table 2) in the nature of the antigen, which is 
obtained in E. coli under native conditions. Under the conditions 
used in this study, the protein forms dimers and trimers like 
it was previously seen by Zheng et  al. (2018). Some of the 
assays presented in Table 2 obtained the antigen under 
denaturing conditions and refolded it after purification. The 
size of our antigen is like most of the antigens used in 
commercial assays. Most of the ELISAs in Table 2 use ORF2 
or combinations with ORF3 from HEV-1. Only three of the 
assays (Mikrogen, DIA.PRO and Biomedical) include ORF2 
or parts thereof belonging to HEV-1 and HEV-3. The ELISA 
from DIA.PRO is based on synthetic peptides covering ORF2 
and ORF3 from different genotypes. We  showed that the 
recombinant HEV-3 ORF2, under the conditions tested in 
this study, is enough to detect anti-HEV IgG with a high 
agreement with the commercial assay [K  =  0.9402 
(0.8731–1.0073)].
About 2.54  μg of the purified protein was used to coat each 
ELISA plate. We estimate that 1972 plates can be prepared from 
1  L bacterial culture (yield  =  4.93  mg/L), which allows testing 
approximately 178,000 serum samples. Results obtained with our 
TABLE 2 | Comparison of commercial ELISA tests for Hepatitis E and the in-house ELISA developed in this study.
Anti-HEV ELISA (IgG) Antigen type Genotype (GT) Antigen size Se1 (%) Sp2 (%) Reference
Wantai Recombinant antigen ORF-2C-
terminal
GT 1 211 aa 97.96 99.6 (Bendall et al., 2010; 




GT 4 210 aa 93.2 97.8 (Park et al., 2012; 
Abravanel et al., 2013)
Axiom Recombinant antigen ORF-2C-
terminal (Burmese strain)
GT 1 n.s 95 98 (Norder et al., 2016)
Mikrogen Recombinant antigen ORF-2C-
terminal
GT 1 and 3 n.s 62 99 (Avellon et al., 2015; 
Norder et al., 2016)
Abbot Recombinant antigen ORF-2 and 
ORF-3 (Burmese strain)
GT 1 ORF2 123 aa
ORF3 full length
60 96 (Psichogiou et al., 
1996; Myint et al., 
2006)
Adaltis Synthetic peptides encoded by 
the ORF-2 and ORF-3
GT 1 and 2 n.s 80 62.9 (Abravanel et al., 
2013; Wu et al., 2014)
MP Biomedical 3 recombinant antigens, ORF-2 
and ORF-3 (Burmese, Mexican 
strains)
GT 1 and US type 2 n.s n.s n.s (Vollmer et al., 2016)
3 recombinant proteins from 
ORF-2 GT2, ORF-3 GT3 and 
ORF-3 GT1
GT 1, 2 and 3 ORF2 GT2
42 aa
ORF3 GT3 33 aa
ORF3 GT1
73.3 65.3 (Schnegg et al., 2013; 
Wu et al., 2014)
Euroimmun Recombinant antigen ORF-2 
(USA strain)
GT 3 n.s 42 99 (Avellon et al., 2015; 
Norder et al., 2016; 
Vollmer et al., 2016)
DIA.PRO 4 synthetic peptides with 
conservative epitopes of ORF-2 
and ORF-3
GT 1, 2, 3, and 4 n.s 98 96 (Avellon et al., 2015; 
Norder et al., 2016)
Genelab Recombinant peptides ORF-2 
and ORF-3C- terminal (Burmese, 
Mexican strains)
GT 1 and 2 n.s 50–90 93–100 (Bendall et al., 2010; 
Park et al., 2012)
DSI Recombinant peptides ORF-2 
and ORF-3
GT 1, 2 and 3 n.s 72 99 (Norder et al., 2016)
This study Recombinant antigen ORF-2C- 
terminal
GT3 496 aa 77.93–99.18* 96.71–99.98*
n.s.: not specified; 1Sensitivity; 2Specificity; *with a 95% confidence interval.
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in-house ELISA highly agree with the ones furnished by the 
commercial assay DIA.PRO HEV IgG ELISA kit. We established 
a cut-off value of A450nm  =  0.498 for the in-house ELISA based 
on the ROC curve analysis (Figure 2B). Figure 2C depicts a 
common problem that several epidemiological studies have faced, 
including HEV seroprevalence studies, because small changes 
in the cut-off value may have a considerable influence on the 
seroprevalence rates.
In Argentina, diagnostic tests are scarcely developed and 
produced, in part because of regulations which prevent patenting 
diagnostic assays. We  aim to offer an alternative to the only 
available assay: a test to be  used in epidemiological studies 
with a similar sensitivity and specificity, but that is able to 
be produced locally at a lower cost. In order to use the in-house 
ELISA for diagnostic purposes, detection of anti-HEV IgM 
should be  evaluated and validated.
The HEV seroprevalence of 9.23% (95% confidence interval, 
7.33–11.43%) is within the range (4.4, 15.8%) found in central 
Argentina (Munne et al., 2011; Martinez Wassaf et al., 2014), 
and 9% found in Buenos Aires in 2012 (Munne et  al., 2014) 
Although the IgG seropositivity does not represent active 
infection or carrier state but a past infection, it suggests 
that infection can be  spread during periods of infectivity. 
Therefore, standardized screening provides an opportunity 
for public health services to address this concern. Indirect 
tests better suit the equipment available in routine laboratories 
in Latin America, where regular molecular testing is 
still uncommon.
Recently, 1–4% of chronic HEV infections were acquired 
by blood transfusion and developed persistent liver graft 
damage (Pawlotsky, 2014). Hewitt et  al. evidenced the 
presence of HEV RNA in blood donations and the 
transmission of HEV through different blood components 
and described the morbidity of infected recipients (Hewitt 
et  al., 2014). Chronic hepatitis E infection in 
immunocompromised patients is a serious issue, which 
may cause cirrhosis leading to liver failure. This underscores 
the new threat that HEV represents to blood transfusion 
safety. Some experts from industrialized countries 
recommend that systematic HEV testing by qRT-PCR should 
be  implemented in blood banks to reduce the existent 
risk of serious complications and death (Hewitt et  al., 
2014). Systematic testing implies practical, economic, and 
logistic issues not currently solvable in Argentina. As 
seroprevalence of HEV changes over time, suggesting that 
some generations have been more exposed than others, it 
seems necessary to implement at least the epidemiological 
surveillance of HEV – with serological methods like the 
in-house ELISA presented here – in order to take public 
health decisions timely. Despite HEV circulation in northern 
Argentina (this study; Martinez Wassaf et  al., 2014; Debes 
et al., 2016; Pisano et al., 2017, 2018a), differential diagnoses 
are barely done at the most important hospitals of Tucuman, 
indicating that HEV is not considered a possible etiologic 
agent. As HEV prevalence worldwide increases in parallel 
with the physicians’ awareness of the disease and the higher 
availability of diagnostic assays, we  expect that this study 
will also raise the interest of health decision makers who 
should intercede to include indirect testing of HEV in 
regular diagnostic protocols.
In conclusion, the in-house ELISA developed in this work 
shows a very good agreement with an already licensed commercial 
HEV IgG ELISA (DIA.PRO, ITALY). We  provide an accessible 
tool for studies to deepen the knowledge on HEV epidemiology 
in Argentina and neighboring countries. Using this in-house 
ELISA, we determined a seroprevalence of 9.23% (95% confidence 
interval, 7.33–11.43%) in northern Argentina.
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